[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100334599":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":19,"locations":28,"responsibleParty":46,"collaborators":49,"id":52,"slug":7,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":7,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Cleveland Clinic Abu Dhabi","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Blood collection","Pharmacokinetics",[13,16],{"name":14,"affiliation":5,"role":15},"Wasim El Nekidy, PharmD","PRINCIPAL_INVESTIGATOR",{"name":17,"affiliation":18,"role":15},"Islam Ghazi, PharmD","University of the Sciences",[20,25],{"name":14,"role":21,"phone":22,"phoneExt":23,"email":24},"CONTACT","+971 2 6590200","47969","ElnekiW@ClevelandClinicAbuDhabi.ae",{"name":17,"role":21,"phone":26,"phoneExt":7,"email":27},"+12152688908","i.ghazi@usciences.edu",[29],{"facility":5,"status":30,"city":31,"state":7,"zip":7,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Abu Dhabi","United Arab Emirates",{"type":34,"coordinates":35},"Point",[36,37],54.39696,24.45118,{"lat":37,"lon":36},[40,44,45],{"name":41,"role":21,"phone":42,"phoneExt":23,"email":43},"Wasim S El Nekidy, PharmD","+97125092000","elnekiw@ccaduae.ae",{"name":14,"role":15,"phone":7,"phoneExt":7,"email":7},{"name":17,"role":15,"phone":7,"phoneExt":7,"email":7},{"type":15,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Wasim El Nekidy","Senior Pharmacotherapy Specialist",[50],{"name":51,"class":6},"University of the Sciences in Philadelphia","100334599",false,"NCT03636464","Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies","Pharmacokinetics and Deposition of Commonly Prescribed Antibiotics in Hospitalized Critically Ill Patients Undergoing Renal Replacement Therapies","RRTdose","Inclusion Criteria:\n\n* Adults \\> 18 year old\n* Prescribed meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam , or piperacillin\u002Ftazobactam for treatment of infection as part of standard medical care\n* Administered meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam ,or piperacillin\u002Ftazobactam while on renal replacement therapy (IHD or CRRT) or renal replacement therapy started while on any of these antibiotics\n* Patients with hemoglobin \\> 70 g\u002FL without blood transfusion in the past 24 hours\n* Informed consent given by patient, next of kin or legally authorized representative\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Pregnant females\n* Body mass index \\\u003C 18 or \\> 35 kg\u002Fm2\n* Presence of anemia (defined as hemoglobin \\\u003C 70 g\u002FL), thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count \\\u003C 75% of the lower limit of normal\n* Concomitant receipt of another cephalosporin interfering with assay\n* Participants likely to require surgical interventions during the study period if the surgery would interfere with dosing intervals or affect sampling process\n* Protected patients; prisoners, patients with HIV, patients with physical or mental disabilities, psychiatric patients.\n* Patients with documented life-threatening allergy (i.e anaphylaxis, angioedema) to any of the study drugs or their class.\n* Patients with conditions known to significantly affect PK; (i.e. severe burn, significant ascites, spinal cord injury and cystic fibrosis)\n* Any other reason felt by the investigators to potentially affect the outcomes of the study","ALL","18 Years",{"count":62,"type":63},200,"ESTIMATED","OBSERVATIONAL","The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime\u002FAvibactam , Ceftolozane\u002FTazobactam , and piperacillin\u002Ftazobactam in the plasma and determine how much is removed by Renal Replacement Therapies to ensure adequate dosing",[67],"Renal Replacement Therapy",[11,69,70],"antibiotics","RRT","2023-02-07",{"date":73,"type":74},"2023-02-08","ACTUAL",{"date":76,"type":74},"2018-04-01",{"date":78,"type":63},"2026-07-01",{"name":5,"class":6},1]